¹Ù·Î°¡±â ¸Þ´º

¹Ù·Î°¡±â ¸Þ´º º»¹®³»¿ë ¹Ù·Î°¡±â ¸ÞÀθ޴º ¹Ù·Î°¡±â

ÁÖ¿ä¾È³»

HOME »çÀÌÆ®¸Ê

FONT SIZE

ÆùƮũ±â Å°¿ò 100% 110% 120% 130% 140% ÆùƮũ±â ÁÙÀÓ
¸Þ´ºº¸±â
 
Á¦¸ñ
5/21 This is a presentation paper
ÀÛ¼ºÀÏ
2022-05-19
Á¶È¸¼ö
175


Greeting,
This is Mingyu Jin.
I am making this post to inform you that I will be presenting this week’s seminar (5/21).

The paper I am going to present is “Human gut bacterial metabolism drives Th17 activation and colitis”.
It was published on Cell Host & Microbe in January 2022.

Intestinal immune responses are linked to the trillions of microorganisms that colonize the gastrointestinal tract. Thus, inter-individual variations in the gut microbiome have been hypothesized to broadly impact immune-related diseases.

Th17 cells exacerbates mouse models of autoimmunity; Yet, the diverse mechanisms of how autoimmune-associated bacteria contribute to Th17 activation and disease are still being elucidated.

Here, they demonstrate that the metabolic activity of human gut bacteria promotes Th17 activation exacerbating colitis severity. Their results add E. lenta to the growing list of immunomodulatory microorganisms relevant to IBD and emphasize the importance of considering the impact of strain-specific microbial metabolism on immune responses and autoimmunity.

E. lenta is associated with human disease and exacerbates colitis in mice.
A strain-specific enzyme Cgr2 induces IL-17a via the metabolism of Rorγt inhibitors.
Dietary arginine blocks E. lenta-induced intestinal inflammation.

With possible applications, such as in the field of Th17 activation and colitis. I believe the findings from this paper surely are interesting.
Please check out the link below to download the full paper.
http://www-sciencedirect-com-s.vpn.scau.edu.cn:8118/science/article/pii/S1931312821005072?via%3Dihub
Best regards.
Mingyu Jin.
÷ºÎÆÄÀÏ:
÷ºÎÆÄÀÏÀÌ ¾ø½À´Ï´Ù.
´ÙÀ½±Û
5/28 ¹ßÇ¥ ³í¹®ÀÔ´Ï´Ù.
/ °ü¸®ÀÚ
¾È³çÇϼ¼¿ä. À̹øÁÖ ¹ßÇ¥ÀÚ ¹Î¼ºÀÔ´Ï´Ù. Á¦°¡ À̹ø¿¡ ¼±Á¤ÇÑ ³í¹®Àº2021³â 'Cell Reports'ÃâÆÇµÈ 'Prostaglandin E2 amplifies IL-17 production by gd T cells during barrier inflammation'ÀÔ´Ï´Ù. À§ ³í¹®Àº PGE2°¡IL-1b¿Í IL-23ÀÇ ÀÚ±Ø ÇÏ¿¡ ¼øÇÑ ¹× Á¶Á÷ ƯÀÌÀûÀÎ gd T cellÀ» ÅëÇØ IL-17 c..
ÀÌÀü±Û
5/21 ¹ßÇ¥³í¹®ÀÔ´Ï´Ù.
/ °ü¸®ÀÚ
¾È³çÇϼ¼¿ä, À̹øÁÖ ¹ßÇ¥ÀÚ ±è¼öÁöÀÔ´Ï´Ù. Á¦°¡ ¼±Á¤ÇÑ ³í¹®ÀºÀ̹ø´ÞPLOS biology¿¡ ÃâÆÇµÈ "Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates" ÀÔ´Ï´Ù. ÇöÀç±îÁö ¸¹Àº COVID19 ¹é½ÅµéÀÌ °³¹ßµÇ¾ú..